BioAtla, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- BioAtla, Inc. pe ratio for the quarter ending 2026-06-30 was -0.21, a change of 0.17 year-over-year.
- BioAtla, Inc. pe ratio for the quarter ending 2026-03-31 was -0.01, a change of 16.37 year-over-year.
- BioAtla, Inc. pe ratio for the quarter ending 2025-12-31 was -0.01, a change of 24.59 year-over-year.
- BioAtla, Inc. pe ratio for the quarter ending 2025-09-30 was -0.62, a change of 51.38 year-over-year.
- BioAtla, Inc. pe ratio for fiscal 2026 was -0.21.
- BioAtla, Inc. pe ratio for fiscal 2025 was -0.01, a change of 24.59 from fiscal 2024.
- BioAtla, Inc. pe ratio for fiscal 2024 was -24.6, a change of 23.29 from fiscal 2023.
- BioAtla, Inc. pe ratio for fiscal 2023 was -47.9, a change of 131.6 from fiscal 2022.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |